{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,2,21]],"date-time":"2025-02-21T08:32:02Z","timestamp":1740126722395,"version":"3.37.3"},"reference-count":3,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2019,1,1]],"date-time":"2019-01-01T00:00:00Z","timestamp":1546300800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/501100006109","name":"VEGA","doi-asserted-by":"publisher","award":["2\/0065\/15"],"award-info":[{"award-number":["2\/0065\/15"]}],"id":[{"id":"10.13039\/501100006109","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100006109","name":"VEGA","doi-asserted-by":"publisher","award":["2\/0155\/16"],"award-info":[{"award-number":["2\/0155\/16"]}],"id":[{"id":"10.13039\/501100006109","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100005357","name":"APVV","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100005357","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.fr","clinicalkey.com.au","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Medical Hypotheses"],"published-print":{"date-parts":[[2019,1]]},"DOI":"10.1016\/j.mehy.2018.10.006","type":"journal-article","created":{"date-parts":[[2018,10,11]],"date-time":"2018-10-11T03:45:16Z","timestamp":1539229516000},"page":"8-9","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"special_numbering":"C","title":["On infusion of high-dose ascorbate in treating cancer: Is it time for N-acetylcysteine pretreatment to enhance susceptibility and to lower side effects?"],"prefix":"10.1016","volume":"122","author":[{"given":"K.","family":"Valachov\u00e1","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"I.","family":"Jur\u00e1nek","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"P.","family":"Rapta","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"I.","family":"Valent","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"L.","family":"\u0160olt\u00e9s","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"9","key":"10.1016\/j.mehy.2018.10.006_b0005","doi-asserted-by":"crossref","first-page":"759","DOI":"10.2174\/138920101609150715135921","article-title":"Treatment of pancreatic cancer with pharmacological ascorbate","volume":"16","author":"Cieslak","year":"2015","journal-title":"Curr Pharm Biotechnol"},{"key":"10.1016\/j.mehy.2018.10.006_b0010","doi-asserted-by":"crossref","first-page":"1867","DOI":"10.1016\/j.polymdegradstab.2009.05.007","article-title":"High-molar-mass hyaluronan degradation by Weissberger\u2019s system: pro- and anti-oxidative effects of some thiol compounds","volume":"94","author":"Hrabarova","year":"2009","journal-title":"Polym Degrad Stab"},{"key":"10.1016\/j.mehy.2018.10.006_b0015","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1159\/000319951","article-title":"Catalytic therapy of cancer by ascorbic acid involves redox cycling of exogenous\/endogenous copper ions and generation of reactive oxygen species","volume":"56","author":"Hadi","year":"2010","journal-title":"Chemotherapy"}],"container-title":["Medical Hypotheses"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0306987718306388?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0306987718306388?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,12,25]],"date-time":"2018-12-25T06:27:00Z","timestamp":1545719220000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0306987718306388"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,1]]},"references-count":3,"alternative-id":["S0306987718306388"],"URL":"https:\/\/doi.org\/10.1016\/j.mehy.2018.10.006","relation":{},"ISSN":["0306-9877"],"issn-type":[{"type":"print","value":"0306-9877"}],"subject":[],"published":{"date-parts":[[2019,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"On infusion of high-dose ascorbate in treating cancer: Is it time for N-acetylcysteine pretreatment to enhance susceptibility and to lower side effects?","name":"articletitle","label":"Article Title"},{"value":"Medical Hypotheses","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.mehy.2018.10.006","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"simple-article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}]}}